Quantinno Capital Management LP Increases Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Quantinno Capital Management LP increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 239.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,736 shares of the medical equipment provider’s stock after purchasing an additional 28,042 shares during the quarter. Quantinno Capital Management LP’s holdings in Zimmer Biomet were worth $4,197,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. increased its position in shares of Zimmer Biomet by 1.2% during the fourth quarter. Assenagon Asset Management S.A. now owns 28,490 shares of the medical equipment provider’s stock worth $3,009,000 after purchasing an additional 345 shares in the last quarter. Gateway Investment Advisers LLC increased its position in Zimmer Biomet by 184.9% during the 4th quarter. Gateway Investment Advisers LLC now owns 6,133 shares of the medical equipment provider’s stock valued at $648,000 after buying an additional 3,980 shares in the last quarter. Wedge Capital Management L L P NC raised its stake in Zimmer Biomet by 1.6% in the fourth quarter. Wedge Capital Management L L P NC now owns 105,920 shares of the medical equipment provider’s stock valued at $11,188,000 after buying an additional 1,688 shares during the last quarter. HB Wealth Management LLC boosted its holdings in Zimmer Biomet by 5.9% in the fourth quarter. HB Wealth Management LLC now owns 4,302 shares of the medical equipment provider’s stock worth $455,000 after acquiring an additional 241 shares in the last quarter. Finally, Romano Brothers AND Company grew its stake in shares of Zimmer Biomet by 1.1% during the fourth quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider’s stock worth $1,000,000 after acquiring an additional 102 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on ZBH. Morgan Stanley lowered their target price on shares of Zimmer Biomet from $115.00 to $95.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 6th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. Barclays cut their target price on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research report on Monday, February 10th. Raymond James lowered their price target on Zimmer Biomet from $119.00 to $104.00 and set an “outperform” rating for the company in a research report on Tuesday, May 6th. Finally, Robert W. Baird cut their price objective on Zimmer Biomet from $130.00 to $115.00 and set an “outperform” rating on the stock in a report on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $113.45.

Zimmer Biomet Stock Up 0.1%

ZBH stock opened at $96.78 on Monday. Zimmer Biomet Holdings, Inc. has a one year low of $89.92 and a one year high of $120.13. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The firm’s fifty day moving average is $103.41 and its 200 day moving average is $105.84. The firm has a market cap of $19.15 billion, a PE ratio of 21.75, a P/E/G ratio of 1.95 and a beta of 0.78.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The business had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The company’s revenue for the quarter was up 1.1% on a year-over-year basis. During the same period in the prior year, the company posted $1.94 EPS. On average, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.99%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.24%.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.39% of the stock is currently owned by corporate insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.